Gain Therapeutics reports positive data from Phase I Parkinson's treatment trial [Yahoo! Finance]
Gain Therapeutics, Inc. (GANX)
Company Research
Source: Yahoo! Finance
The trial assessed the safety, tolerability, and pharmacokinetics of GT-02287 for the potential treatment of Parkinson's. It included 72 healthy male and female volunteers aged up to 64 years. The company previously reported that no discontinuations or serious adverse events were observed at the conclusion of the trial. The unblinded data review post-database lock confirmed that GT-02287 was found to be safe and well-tolerated at all dose levels, including the highest planned doses. GT-02287's presence in the cerebrospinal fluid (CSF) indicated central nervous system (CNS) exposure and peripheral target engagement. The favourable safety and tolerability profile of GT-02287 at oral doses that achieved therapeutic plasma levels, CNS exposure, and target engagement enhances its potential as a leading treatment for Parkinson's disease, whether or not patients have a GBA1 mutation. A brain-penetrant small molecule, the drug acts as an allosteric protein modulator that restores
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics GAAP EPS of -$0.17 [Seeking Alpha]Seeking Alpha
- Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate UpdateGlobeNewswire
- Gain Therapeutics Presents Data at 36?? EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2GlobeNewswire
- Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewswire
GANX
Earnings
- 11/14/24 - Beat
GANX
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 10/21/24 - Form 8-K
- GANX's page on the SEC website